|
- GV1001 - ALZFORUM
Originally developed as a cancer vaccine, GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT) Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells
- Efficacy and safety of GV1001 in patients with moderate-to-severe . . .
This phase 2 trial showed that GV1001 may provide beneficial effects without safety concerns in patients with moderate-to-severe AD GV1001 1 12 mg met the primary endpoint, and this study warrants a larger clinical trial
- GemVax Receives FDA Phase 2 IND Approval for GV1001 in the Treatment . . .
GemVax KAEL Co , Ltd (GemVax, 082270) announced on the 13th that the U S Food and Drug Administration (FDA) approved their Investigational New Drug (IND) application for a Phase 2 clinical trial of GV1001, aimed at treating progressive supranuclear palsy (PSP), on October 9 (local time)
- GV-1001: unclear news is good news | PSP Blog
Now, the issue is just how safe and tolerable the drug was The press release only says, “The safety profile of GV1001 in the Phase 2a PSP Clinical Trial was consistent with prior safety data GV1001 was generally well-tolerated with no serious adverse events related to the drug reported ”
- GV1001 Shows Promise in Moderate to Severe Alzheimers, Study Says
Treatment with GV1001 provided benefits for adults with moderate to severe Alzheimer’s, who take Aricept for dementia, Phase 2 trial show
- Subgroup Analyses Give Weight for Next-Level Trial of GV1001 in . . .
Originally developed as a cancer vaccine, GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT) It is currently being investigated in a phase 2 study in patients with Alzheimer disease (AD) that is currently slated to finish up in 2026
- Efficacy and safety of GV1001 in patients with moderate-to-severe . . .
This clinical trial showed that GV1001, especially at a dose of 1 12 mg, effectively reduced the change in SIB scores compared with the placebo treatment, suggesting that GV1001 might have beneficial effects in patients with moderate-to-severe AD
- Efficacy of GV1001 with gemcitabine capecitabine in previously . . . - Nature
The TeloVac study indicated GV1001 did not improve the survival of advanced pancreatic ductal adenocarcinoma (PDAC)
|
|
|